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Abstract
Struma ovarii is a rare tumor. Malignant change in this tumour is even rarer. While clinical presentation is 
protean, a preoperative diagnosis is equally difficult. Diagnosis is confirmed by histology. Treatment of 
malignant struma ovarii is by surgical resection of the tumor or total abdominal hysterectomy and 
bilateral salpingo-oophorectomy. A total thyroidectomy allows radioactive iodine ablation and the use 
of thyroglobulin as marker to monitor recurrence. However due to rarity of the disease, standard 
treatment is still controversial. We present a case of malignant struma ovarii, followed up for five years 
after treatment, and a review of the literature on the disease. The patient was treated with surgery and 
radiation. She is still free of disease after 5 years.
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Introduction Progression of patient's symptoms led to a 
Struma ovarii is a rare tumor, accounting for laparatomy. Operative findings showed normal 
1approximately 1% of all ovarian tumors . It is a sized right ovary with small cysts which 
monodermal variant of ovarian teratomas in contained serous fluid. The left ovary was 
which thyroid tissue is the major constituent enlarged, had multilocular cysts containing 
2, 3 sebaceous materials, hair and serous fluid. The (>50%) . Struma ovarii constitutes only 2.7 % of 
4 uterus was grossly unremarkable. mature cystic teratomas . Malignant struma 
ovarii is even much rarer, being seen in just about 
5, 6 A total abdominal hysterectomy (TAH) with or less than 5% of struma ovarii . 
bilateral salpingo-oophorectomy (BSO) was 
carried out. The histopathology revealed that the Clinical Case 
0 left ovary had features of mature cystic teratoma We present a 44year old Para 2+  female who was 
with malignant transformation in thyroid tissue first seen at an Indian hospital about June 2005 
consistent with papillary thyroid carcinoma. Post when she presented with a history of worsening 
operatively, serum alpha fetoprotein level was lower abdominal pains. The pain was not 
7ng/ml, CA-125 was 2U/ml, â HCG was relieved by analgesics. There was no known 
<0.05mIU/ml.precipitating or aggravating factor. There was no 
CT scan of the abdomen scan as well as thyroid unusual vaginal bleeding or discharge. Her last 
ultrasound scan done two months post confinement was 26 years prior to presentation. 
operatively were normal. A base line thyroid There was no past or current use of intrauterine 
function test showed T3 (1.7µg/dl), T4 contraceptive devices. Her menstrual cycle had 
(9.5µg/dl), TSH (5.3µIU/ml). This was followed been fairly regular. She was not a known peptic 
by a pertechnetate (TcO4) thyroid uptake test, ulcer patient.
which showed uniform uptake in both thyroid 
lobes. No abnormal extra-thyroidal uptake was Ultrasonography of the abdomen showed a left 
seen. A near total thyroidectomy (NTT) was adnexal mass measuring 37mm x 35mm in the 
transverse plane. The mass was anechoic and 
had posterior acoustic enhancement. The uterus 
and contralateral ovary were essentially normal 
but minimal fluid was seen in the pouch of 
Douglas. An impression of a functional left 
ovarian cyst was made with a request for clinical 
correlation.
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carried out in November 2005.  Histology of the and rarely, thyroid tumors (10, 11). In a series Yoo 
thyroid specimen showed no evidence of and co-workers (12) found 14 out of 34 patients 
malignancy in the sections examined and patient had no symptoms at all. 
was discharged on thyroxin replacement and Ultrasound cannot specifically identify struma 
referred for remnant ablation. ovarii; however one must consider this diagnosis 
especially in solid looking teratomas. 
131In July 2006, an ablative dose of 100 mCi I was Preoperative diagnosis of struma ovarii is only 
administered. Post therapy scan showed only possible in patients with hyperthyroidism by 
remnant uptake in the thyroid bed and patient measurement of serum TSH in combination with 
123was discharged on thyroxine replacement. A I scintigraphy. (13) Although no preoperative 
131 123
stimulated diagnostic I scan was done later and I scan was done in this patient, the diagnostic 
it confirmed the success of the ablation. She is dilemma was worsened because the trans-
being followed up with yearly clinical reviews abdominal ultrasound scan failed to detect the 
including physical examinations, thyroid solid component of the cyst. From our 
function tests, thyroglobulin (Tg) and anti experience, barring the limitations from very 
thyroglobulin antibody (ATA) assays and has so large ovarian tumors, trans-vaginal scans 
far been disease free. Her last thyroid function whenever possible usually provide images with 
tests (done in March 2010) recorded sufficient and better resolution to improve the 
undetectable thyroglobulin levels and TSH was differential diagnosis of ovarian masses. 
2.0µIU/l. However, at best ultrasound picture in struma 
ovarii is not much different from a mature cystic 
Discussion teratoma. (14)
Struma ovarii was described by Von Kalden in 
1895, and Gottschalk and Mayer in 1903. (7, 8)  There is no universal therapy for malignant 
The incidence of malignant struma ovarii is said struma ovarii throughout literature. Surgery 
to be only 5% of all struma ovarii cases. Thyroid v a r i e s  f r o m  l a p a r o s c o p i c  u n i l a t e ra l  
element can be noted in almost 20% of ovarian oophorectomy to total abdominal hysterectomy 
teratomas, however, the term 'struma' is used with bilateral salpingo- oophorectomy (TAH+ 
when the thyroid tissue constitutes more than BSO) with omentectomy. 
50% of the tumor (5, 6). Even though it is a Devany (13) and co-workers have urged the use 
neoplasm consisting of thyroid tissue, only 8% of of the same histological criteria to diagnose 
patients with struma ovarii present with clinical malignant struma ovarii as that used for tumors 
hyperthyroidism (9). This low incidence is in the thyroid. Others maintain the histologic 
reflected in this patient who showed no clinical criteria for malignancy may be different from 
or laboratory features of hyperthyroidism. those of thyroid carcinoma, invasive growth 
being difficult to appreciate and papillary 
Clinical symptoms that may manifest due to the formations may not be conclusive. The diagnosis 
presence of struma ovarii are lower abdominal may rely on the presence of cellular atypia (15, 
pains, palpable lower abdominal mass, 16). This however seemed not to be the case in 
abnormal vaginal bleeding, ascites, hydrothorax our patient where typical features papillary 
carcinoma allowed a confident diagnosis. interruption of thyroid substitution. (22) Except 
There was no apparent metastasis in our patient for the diagnostic scan to confirm ablation, we 
131did not have cause to repeat a I WBS in the 5 as evidenced by negative extra thyroidal bed 
131
uptake after the therapeutic I whole body scan years of following up this patient. The thyroid 
(WBS) and undetected thyroglobulin levels till function tests, serum thyroglobulin and anti 
date. Indeed metastatic struma ovarii is rare, and thyroglobulin antibody (ATA) assays have so far 
so are aggressive histologic variants like mixed remained excellent indices to monitor 
adenocarcinoma, Hurtle cells and anaplastic recurrence.                                      
carcinoma though they have been described 
(17). Contributory to the absence of metastasis The widely accepted tumor marker of ovarian 
in this patient also include the early diagnosis cancers CA-125 is found to be increased in 80% of 
and aggressive intervention (surgical and epithelial ovarian carcinomas. This marker is also 
radioiodine ablation and a follow up TSH elevated in other tumorous lesions of the 
suppression). endometrium, intestines, breasts, and lungs as 
Total thyroidectomy following surgical removal well as in non malignant related gynecologic 
of the ovarian lesion allows the exclusion of conditions, thus indicating that there is a limit to 
primary thyroid carcinoma with metastasis to the clinical application of CA-125 as a tumor 
131
the ovary and in addition, allows radioiodine ( I) marker of ovarian neoplasms. Moreover, it has 
for the treatment of micro-metastasis. After been postulated that increased levels of CA-125 
total thyroidectomy, thyroglobulin can be used is not a direct consequence of the presence of 
as a tumor marker for follow up (18). The malignant tumor, but rather a secondary effect 
presence of a primary thyroid carcinoma must be due the presence of ascites. (23)
excluded. (19) 
In the case series by Yoo et al (12), it was 
Management of patients who desire fertility observed that CA-125 was increased in 4 among 
might be challenging. (9) Another challenge 13 patients with struma ovarii (3 malignant and 
sometimes encountered fact is a patient's refusal 10 benign). This comprised of 1 out of the 3 
to accept thyroidectomy, as shown by Yücesoy et malignant cases and 3 of the 10 benign cases. The 
al (20). Patients treated without thyroidectomy elevation in the malignant case was minimal. 
with survival rates of 12- 180 months have been This, coupled with the presence of elevations in 
reported. (21) In struma ovarii, peritoneal fluid benign struma ovarii cases caused them to 
levels of thyroglobulin might indicate an intra- propose that serum CA-125 measurements are 
abdominal extension or recurrence. Follow up by of little clinical value in struma ovarii patients. In 
means of this marker obviates the need for the case we report the patient had no ascites and 
131 the CA-125 level was normal.repeated I scanning and the unpleasant 
hypothyroid symptoms inherent to the 
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